Roland Griffiths forced institutional medicine to acknowledge an experience it had excluded. Under carefully prepared conditions, psilocybin reliably occasions encounters that participants rank among the most meaningful of their lives. His work made mystical phenomenology, the qualities of mystical experience, a legitimate subject for science. It also preserved the larger question of what the experience reaches.
The Scientist Before the Turn
Roland Ray Griffiths (1946–2023) spent his first three research decades within mainstream psychopharmacology, the study of drugs’ effects on mind and behavior. He was among its most productive and conventionally respected American researchers. In 1972, shortly after his doctorate, he joined the Johns Hopkins University School of Medicine faculty. He remained there throughout his working life.
His early work studied how drugs reinforce their own use in animals and humans. He measured how substances produce and sustain dependence, and how people experience their effects. He also developed methods that distinguished pharmacological reinforcement from placebo and expectation. This rigorous work stayed within conventional behavioral pharmacology.
Griffiths published several hundred peer-reviewed papers on caffeine, nicotine, benzodiazepines, opioids, and other standard targets. By the late 1990s, he was a senior figure in the field. His first thirty years gave little indication of the role that followed. He became the most consequential figure in the twenty-first-century revival of psychedelic research.
The turn began with meditation. Griffiths took up Siddha Yoga in 1994 while questioning his career’s purpose. He later described doubts about whether quantifying drug effects contributed to anything he considered important. Meditation brought profound peace, unity, and states that felt ontologically distinct: different in their mode of being. His professional materialism did not accommodate these experiences.
For several years, Griffiths continued conventional research alongside meditation. He did not immediately make the experiences a research program. Their recurrence instead led him to question whether his training adequately described what he encountered.
Around 1999–2000, he read psilocybin research conducted before the 1970 Controlled Substances Act closed the field. Walter Pahnke’s 1962 Good Friday Experiment at Marsh Chapel was especially important. Pahnke conducted it as Harvard Divinity School dissertation research. Leary’s Harvard Psilocybin Project supplied the psilocybin.
The earlier studies used controlled administration and structured questionnaires to compare psilocybin experiences with mystical states described in spiritual literature. Pahnke’s divinity students received psilocybin in a chapel. They reported experiences that scored highly on measures of mystical consciousness. They also described them as major spiritual events in their lives.
The early findings were affirmative, but the methods were crude by modern standards. Political conditions prevented the necessary follow-up. The interruption left the program without definitive results.
Griffiths saw both opportunity and institutional risk in the thirty-year gap. Modern methods, sample sizes, and outcome measures offered a way to address Pahnke’s unfinished questions. Psilocybin remained a Schedule I substance in the United States. No American researcher had conducted a psilocybin administration study for nearly three decades. Regulatory, ethical, and funding arrangements obstructed the proposed work.
He chose to navigate those arrangements with his senior career capital and Johns Hopkins base. His earlier research had never predicted this program. The decision supplied the institutional beginning of the twenty-first-century psychedelic renaissance.
The 2006 Paper
Griffiths’s team published its founding paper in Psychopharmacology in July 2006:
“Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.”
The study enrolled thirty-six healthy volunteers with no previous psychedelic experience. Selection criteria required stable personalities and active involvement in religious or spiritual activities of their choice. Each participant received two sessions in a double-blind crossover design. That design concealed assignments while letting participants receive both treatments in separate sessions.
One session used thirty milligrams of psilocybin per seventy kilograms of body weight. The other used methylphenidate as an active placebo. Its noticeable drug effects made it a comparator beyond an inert substance. Sessions took place in a comfortable, living-room-style environment with two trained “monitors” providing support. Participants lay on a couch with eyeshades and classical music through headphones, turning attention inward.
Twenty-two of the thirty-six participants, sixty-one percent, met the Pahnke-Richards Mystical Experience Questionnaire’s criteria for a “complete” mystical experience. This threshold requires high scores across several dimensions. Unity dissolves the distinction between self and environment. Other dimensions measure transcendence of time and space, sacredness, and noetic quality: the sense of receiving genuine knowledge. Strongly felt positive mood and ineffability, difficulty expressing the experience, complete the measures.
Two-thirds ranked the session among their five most personally meaningful experiences. They compared it with a first child’s birth or a parent’s death. One-third ranked it as their single most meaningful experience. Follow-up at two months found measurable, lasting changes in attitudes toward self, life, and spirituality. The methylphenidate sessions had not produced those changes.
These findings provided the first institutionally rigorous demonstration of experiences described for centuries in mystical literature. Their content was familiar to the tradition. Mystical writings had described such changes for two millennia. Huxley reported them after mescaline in 1953, and pre-prohibition research had offered preliminary confirmation. People familiar with psychedelics had reason to expect the result.
The decisive change concerned institutional admissibility. A controlled trial used an active placebo, standardized administration, validated measures, and peer-reviewed publication in a reputable journal. A senior biomedical researcher had produced quantified evidence through the establishment’s own methods. Institutions that dismissed mystical experience as confabulation or drug-induced delusion now had to address that evidence.
The tradition already knew the experience. Griffiths made that knowledge admissible within contemporary science’s bureaucracy. Institutional recognition determines whether a finding that exists can enter research, funding, and treatment. His paper opened that channel.
The Subsequent Program
The Johns Hopkins Center for Psychedelic and Consciousness Research opened in September 2019 with Griffiths as founding director. It became the institutional center of the research revival. Subsequent studies examined tobacco addiction, depression, and end-of-life anxiety in cancer patients. Their findings were unusually strong by psychiatric trial standards.
The tobacco study reported eighty percent smoking cessation at six months. That rate exceeded any pharmacological or behavioral intervention reported in the literature. The depression study reported sustained improvement in treatment-resistant patients who had failed several earlier therapies. The cancer study found dramatic reductions in death-related fear and existential distress. Patients who died before follow-up ended retained these reductions during the remainder of their lives.
The clinical studies accompanied a wider program on experience itself. The team developed and validated new Mystical Experience Questionnaire versions. Dose-response studies investigated the thresholds at which mystical experiences reliably emerge. Follow-up showed attitudinal and behavioral changes persisting for fourteen months and longer.
The researchers examined what the experiences contained, including transpersonal states that exceeded the ordinary sense of an individual self. They studied encounters with entities or intelligences and the process of integrating an experience afterward. They also investigated predictors of lasting benefit or psychological difficulty. This work exceeded the usual pharmaceutical trial’s attention to symptoms alone.
Methods remained cautious, and published conclusions conservative. The cumulative program established that supported high-dose psilocybin experiences cannot be adequately described as symptoms. Their consequences were measurable, lasting, and generally positive for participants.
FDA Breakthrough Therapy Designations gave the findings institutional recognition short of approval. Compass Pathways received the designation for COMP360 in treatment-resistant depression in 2018. Usona Institute received it for psilocybin in major depressive disorder in November 2019. Both developments rested on the evidentiary foundation Griffiths’s program built.
The designations placed psilocybin on a regulatory fast-track unavailable to classic psychedelics since the scheduling era. They acknowledged that the research warranted priority engagement without guaranteeing approval. This was the regulatory apparatus’s strongest signal of support for psychedelic medicine.
The God Encounter Studies
Griffiths later investigated reported encounters with God or a divine being. His team’s 2019 paper was titled:
“Survey of Subjective ‘God Encounter Experiences’: Comparisons Among Naturally Occurring Experiences and Those Occasioned by the Classic Psychedelics Psilocybin, LSD, Ayahuasca, or DMT”
The survey analyzed responses from approximately four thousand participants. Their reports addressed questions the perennial philosophy had raised for centuries and institutional science had refused to engage. Some encounters occurred through meditation, prayer, or spontaneous mystical events. Others followed classic psychedelics.
Participants described the encounters in similar language across these categories. Psychedelic encounters received higher ratings for dramatic and enduring changes in existential orientation, their relation to life’s meaning and reality. The central phenomenology remained continuous with naturally occurring mystical experience.
Many people who had identified as atheists no longer did so afterward. People with conventional religious beliefs often described a shift toward experiential understanding. Direct experience gained authority over propositions they had previously accepted.
A survey carries less evidentiary weight than a controlled trial. Its institutional significance was larger than that methodological limit. A senior Johns Hopkins psychopharmacologist researched God encounters and published the results in a peer-reviewed journal. He treated the reports as evidence about experience rather than symptoms of drug-induced confusion.
That choice opened methodological territory closed since prohibition. Whether the program will remain in that territory or become absorbed into conventional medicalization remains unresolved.
The Death
Griffiths received a stage IV colon cancer diagnosis in November 2021. He continued research and publication throughout his remaining life. He also participated in end-of-life studies of the kind his team conducted with other patients. His diagnosis entered the research from the participant’s side.
He reported the experience publicly through interviews that entered the tradition’s death-and-dying literature. In December 2022, he discussed his diagnosis with Tim Ferriss in episode #641. The conversation covered his research, personal engagement with mystical experience, and spiritual evolution. His direct account expressed meanings that his published papers had bracketed.
Griffiths died on October 16, 2023, aged seventy-seven. His interviews, late reflections, and papers preserved his testimony for others. He described growing confidence in the phenomena’s reality and the mystical framework’s adequacy as an account of them.
His death echoes Huxley’s death sixty years earlier. Both used the recovered pharmakon, the substance that serves as medicine and spiritual instrument, at life’s end. Both approached death with preparation unavailable through their secular education. Both documented the process for people who would later face death without that preparation.
The sequence begins with Huxley’s preparation in the 1940s and his LSD death in 1963. Griffiths encountered the research literature around 1999–2000 and later engaged the pharmakon while approaching death. The exact correspondence with Huxley’s deathbed rite remains unresolved. The transmission through their written record carries a continuity that institutional histories have inadequately recognized.
Huxley’s writing preserved the pharmakon tradition and transmitted it to Griffiths. Griffiths extended that recovery through the research his institutional position made possible. He then handed it forward to the generation that inherits their combined work.
The Risk of Success
Griffiths recognized that institutional legitimacy carried risks. Johns Hopkins supplied the movement’s most credible institutional platform. That credibility required methodological choices that narrowed its scope. The tradition stood to lose part of its purpose through those choices.
The clinical protocol administers psilocybin for diagnosable conditions within biomedical research. Screened participants receive supervision from credentialed therapists in institutional settings. The FDA, NIH, insurers, and academic medical centers recognize that arrangement. The pharmakon tradition has regarded it as insufficient for the substance’s full operation.
Institutional capture would preserve approved treatment while excluding the wider cultural and spiritual purpose. Narrowly defined indications would remain within pharmaceutical orthodoxy. Psilocybin would become another patented commercial product, prescribed for depression in the manner of SSRIs. The mystical experience would become an incidental side effect. Its reliable occurrence would count as a drug feature rather than the administration’s purpose.
That channel would exclude traditional use and teacher-student lineage. Ceremonial and cultural contexts would also fall outside it. A prepared vessel’s fundamental reorientation would disappear from the recognized purpose of treatment. Most people’s access would then depend on an institution unable to carry the tradition’s full meaning.
Griffiths named this risk in later interviews and offered no simple answer. At the program’s beginning, he faced a choice between institutional legitimacy and continued marginalization. Marginalization would leave the substance inaccessible to many people who stood to benefit. He chose legitimacy while recognizing the risk of producing the outcome he sought to prevent.
His later work kept the larger purpose alive within the narrowing architecture. God-encounter studies and attention to experience’s content carried that effort. He refused to reduce the experience to a list of therapeutic indications.
The post-2023 regulatory record gave the access problem concrete form. In August 2024, the FDA rejected Lykos Therapeutics’ application for MDMA-assisted psychotherapy for PTSD through a Complete Response Letter. This was the first psychedelic-assisted therapy to complete full regulatory review and the first turned back. The rejection cited trial-design deficiencies, functional unblinding, and questions about therapist conduct. Functional unblinding occurs when noticeable effects reveal treatment assignments despite formal concealment.
In October 2024, Compass Pathways delayed its Phase 3 trial readout and announced a thirty-percent workforce reduction. It held a Breakthrough Therapy Designation for psilocybin in treatment-resistant depression. The company cited the Lykos rejection as a sign of increased regulatory difficulty across the sector.
Oregon’s licensed psilocybin program launched in 2023 as the first state-level legal access pathway. By late 2025, high costs, restricted facilitator capacity, and attrition among licensed service centers had become structural problems. Griffiths’s institutional opening remained real. Normalized access proved more contested than the 2019 moment had suggested.
The program’s internal record also became more complicated. Matthew Johnson was Griffiths’s longtime collaborator and a co-author on the smoking-cessation paper. For years, he supplied credible insider testimony about the program’s rigor. In 2024, he publicly questioned the soundness of research in Griffiths’s lab.
Brendan Borrell reported Johnson’s concerns in a March 2024 New York Times article. This became the most significant challenge from within the program to the renaissance’s evidentiary claims. The criticism concerns whether foundational data fully support the conclusions built upon them. That question differs from the risk of institutions capturing an otherwise valid spiritual practice.
Translating Tradition into Institutional Science
Griffiths translated traditional practice into the language and methods institutions recognized. He preserved enough of the practice to make its experience scientifically admissible without substantially distorting its purpose. The translation was imperfect because biomedical language cannot carry everything the tradition knew. It was also necessary because institutional science controls cultural legitimacy and much of the population’s access.
Consensus reality, the shared world stabilized through perception and institutions, admits phenomena through channels its gatekeepers recognize. Griffiths opened one such channel. His translation made the door available while preserving a recognizable destination for the tradition.
His work belongs to a longer recovery. Eleusis was destroyed in 396 CE. Hofmann recovered the chemistry in 1943. Huxley recovered the framework in 1954. The counterculture disseminated it prematurely in the 1960s, and the orthodoxy suppressed it in 1970. An underground tradition preserved fragments through prohibition.
Griffiths reopened the institutional channel in 2006. The contemporary renaissance continues that recovery. Its completion remains unfinished and, if achieved, will take generations rather than years. His institutional opening gives the tradition a place from which to recover mainstream access.
The next generation determines what returns through that opening. Researchers, clinicians, traditional practitioners, and participants jointly shape the result. They can preserve the tradition’s purpose or substitute a medicalized approximation that institutions can absorb. Access carries the recovered practice forward only when it also carries what the practice is for.
Open Questions
- Will FDA approval preserve the protocols’ fidelity to mystical experience? Or will regulation narrow treatment away from what the original research identified as beneficial?
- Are protocol experiences identical to, continuous with, or distinct from historical mystical experience? Which methods can settle those relations definitively?
- What proportion of clinical benefit depends on mystical experience rather than pharmacological effects? How can protocols maximize that contribution without making it incidental?
- Can traditional teacher-student lineage enter institutional psychedelic therapy? Are their structures compatible?
- Did Griffiths leave a specific succession plan? Who holds institutional authority to continue his research direction?
References
Griffiths, Roland R., et al. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology 187, no. 3 (2006): 268–283.
Griffiths, Roland R., et al. “Mystical-type Experiences Occasioned by Psilocybin Mediate the Attribution of Personal Meaning and Spiritual Significance 14 Months Later.” Journal of Psychopharmacology 22, no. 6 (2008): 621–632.
Griffiths, Roland R., et al. “Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer.” Journal of Psychopharmacology 30, no. 12 (2016): 1181–1197.
Griffiths, Roland R., et al. “Survey of Subjective ‘God Encounter Experiences’: Comparisons Among Naturally Occurring Experiences and Those Occasioned by the Classic Psychedelics Psilocybin, LSD, Ayahuasca, or DMT.” PLOS ONE 14, no. 4 (2019).
Johnson, Matthew W., et al. “Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction.” Journal of Psychopharmacology 28, no. 11 (2014): 983–992.
MacLean, Katherine A., Matthew W. Johnson, and Roland R. Griffiths. “Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness.” Journal of Psychopharmacology 25, no. 11 (2011): 1453–1461.
Borrell, Brendan. “The Psychedelic Evangelist.” New York Times, March 21, 2024.
Ferriss, Tim. “Dr. Roland Griffiths — Psilocybin Research, Mystical Experiences, and the Aftereffects of His Cancer Diagnosis.” The Tim Ferriss Show, episode #641, December 20, 2022. Transcript at tim.blog.
Pahnke, Walter N. “Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness.” PhD diss., Harvard University, 1963.
Pollan, Michael. How to Change Your Mind. Penguin Press, 2018.
Richards, William A. Sacred Knowledge: Psychedelics and Religious Experiences. Columbia University Press, 2016.